spasticity

Less-frequent Dosing with Arbaclofen ER Tablets Decreases Spasticity As Well As Standard Baclofen, MS Trial Data Show

Arbaclofen extended-release (ER) tablets taken twice a day can effectively reduce spasticityĀ (muscle stiffness) in patients with multiple sclerosis (MS) with similar potency to that of standard and more-frequently-dosedĀ baclofenĀ (brand name Lioresal), Phase 3 clinical trials show. Latest trial data were presented in two posters during the 33rd Annual Meeting…

Axim Improves Delivery of Cannabinoids in Chewing Gums

Axim Biotechnologies announced that it has succeeded in microencapsulating cannabinoids (chemical compounds in cannabis) into the companyā€™s patented chewing gums, which are used to treat several disease symptoms, including pain and spasticity associated withĀ multiple sclerosis (MS). Since the active cannabinoids are degradable in the body, the company needed…

Direct Nerve Stimulation Using MyoRegulator System Seen to Reduce Spasticity in Mice with Spinal Injury

Treatment with PathMaker Neurosystemsā€™ anodal transā€spinal direct current stimulation (tsDCS), aĀ non-invasive direct nerve stimulation tool called MyoRegulator, was found to effectively easeĀ spasticity in mice with spinal cord injury, a study reports. A link between the ability to control muscle contraction and the levels of a specific neuronal…

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity

WeHealth by Servier and PathMaker Neurosystems have established a new partnership to develop and commercialize the first neuromodulation technology for noninvasive treatment of spasticity, the companies announced. The agreementĀ establishes an exclusive worldwide distribution arrangement, except for the U.S. and Japan, for PathMakerā€™sĀ MyoRegulator. The MyoRegulator uses two pairs of…

MedChew RX Shows Stability and Potential for Effectiveness in Early Tests, Company Reports

AXIM BiotechĀ announced that tests done on itsĀ cannabinoid-based chewing gum ā€”Ā MedChew RxĀ ā€” showed both product stability and effective release of medicinal molecules,Ā with a high percentage of itsĀ pharmaceutical ingredients available. These test results may be of importance, as the company is planning to bring MedChew Rx into clinical trials as a…

PathMaker Neurosystems, Developing MyoRegulator for Spasticity, Named Startup of Year at French-American Business Gala

PathMaker Neurosystems, which specializes in non-invasive devices to treat chronic neuromotor disorders, won theĀ 2018 French-American Business (FAB) AwardĀ in the startup/small company category. PathMaker, based in Boston, is developed and testingĀ MyoRegulator, a potential treatment forĀ muscle spasticity in people withĀ multiple sclerosis (MS), cerebral palsy and other chronic conditions.

Sativex Can Improve Driving Ability of MS Patients, Study Says

Sativex, a cannabis-based anti-spasticity medicine commercialized as oromucosal spray by GW Pharmaceuticals, improves the driving ability of patients with multiple sclerosis (MS), according to researchers. The findings were published in the journal Brain and Behavior, in a study titled ā€œThe influence of THC:CBD oromucosal spray…